Global Aneurysmal Subarachnoid Hemorrhage

Aneurysmal Subarachnoid Hemorrhage Comprehensive Study by Type (Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Lumbar Puncture, Xanthochromia, Cerebral Angiography, Transcranial Doppler Ultrasound), Application (Hospitals, Clinics, Others), Drug Class (Calcium Channel Blocker, Opioid Analgesic, Osmotic Agent, Anticonvulsant, Stool Softener, Others) Players and Region - Global Market Outlook to 2030

Aneurysmal Subarachnoid Hemorrhage Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Aneurysmal Subarachnoid Hemorrhage
Aneurysmal subarachnoid hemorrhage (ASH) is a type of stroke that is life threatening. It exhibits high rates of fatality and permanent disability. ASH is caused due to head injury and hence, it results into stroke. According to a literature review, after ASH, approximately 33% of patients recover and live healthy life; 33% of them survive but live along with some kind of disability, and the rest of patients die. Growing awareness and technological assessments in upcoming medical devices and diagnostic imaging technologies are encouraging people to opt for modern treatment procedures to treat giant surgical and brain hemorrhage procedures. This is anticipated to boost the growth of aneurysmal subarachnoid hemorrhage market.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


In this market, companies are completely focused on research and development to develop drugs or devices. The companies are exploring the market in new regions by expansions, investments, collaboration, and partnership as their preferred strategies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Aneurysmal Subarachnoid Hemorrhage market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Edge Therapeutics, Inc. (United States), Actelion Pharmaceuticals Ltd. (Switzerland), Arbor Pharmaceuticals Inc. (United States), Mayfield Brain & Spine (United States), GE Healthcare (United States), Koninklijke Philips N.V. (Netherland), Siemens AG (Germany), Trivitron Healthcare (India) and Toshiba Medical Systems Corporation (Japan) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Aneurysmal Subarachnoid Hemorrhage market by Type (Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Lumbar Puncture, Xanthochromia, Cerebral Angiography and Transcranial Doppler Ultrasound), Application (Hospitals, Clinics and Others) and Region.



On the basis of geography, the market of Aneurysmal Subarachnoid Hemorrhage has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Class, the sub-segment i.e. Calcium Channel Blocker will boost the Aneurysmal Subarachnoid Hemorrhage market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements in the Treatment and Devices Used for Postpartum hemorrhage and Rising Number of Clinical Trials

Market Growth Drivers:
Increasing Prevalence of Stroke and Hypertension and Lifestyle modifications which increase the risk of aSAH

Challenges:
The Dearth of Skilled Healthcare Providers and Adverse Effects Associated with Drugs

Restraints:
Lack of Awareness in Underdeveloped Countries and Stringent Regulations for Newer Drug Approval

Opportunities:
Increasing Healthcare Expenditure and Rise in R&D Activities for the Innovation of Newer Drugs

Market Leaders and their expansionary development strategies
On December 15, 2023, MicroVention, Inc., a developer of neurovascular solutions, announced its acquisition by Terumo Corporation, a global leader in medical technology. This merger strengthens Terumo's neurovascular portfolio and expands its reach in the SAH treatment market.
In December 2023, Acumen, a subsidiary of Stryker, launched the Pipeline Flex with Emboshield technology, a next-generation flow diversion device for treating wide-neck intracranial aneurysms. This device features a more flexible design and improved embolic stability.


Key Target Audience
New Entrants/Investors in Drugs, Aneurysmal Subarachnoid Hemorrhage Drug Manufacturers, Drugs Raw Material Suppliers, Government Regulatory and Research Organizations, R&D Institutions and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Computed Tomography (CT) Scan
  • Magnetic Resonance Imaging (MRI)
  • Lumbar Puncture
  • Xanthochromia
  • Cerebral Angiography
  • Transcranial Doppler Ultrasound
By Application
  • Hospitals
  • Clinics
  • Others
By Drug Class
  • Calcium Channel Blocker
  • Opioid Analgesic
  • Osmotic Agent
  • Anticonvulsant
  • Stool Softener
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Stroke and Hypertension
      • 3.2.2. Lifestyle modifications which increase the risk of aSAH
    • 3.3. Market Challenges
      • 3.3.1. The Dearth of Skilled Healthcare Providers
      • 3.3.2. Adverse Effects Associated with Drugs
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in the Treatment and Devices Used for Postpartum hemorrhage
      • 3.4.2. Rising Number of Clinical Trials
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Aneurysmal Subarachnoid Hemorrhage, by Type, Application, Drug Class and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Aneurysmal Subarachnoid Hemorrhage (Value)
      • 5.2.1. Global Aneurysmal Subarachnoid Hemorrhage by: Type (Value)
        • 5.2.1.1. Computed Tomography (CT) Scan
        • 5.2.1.2. Magnetic Resonance Imaging (MRI)
        • 5.2.1.3. Lumbar Puncture
        • 5.2.1.4. Xanthochromia
        • 5.2.1.5. Cerebral Angiography
        • 5.2.1.6. Transcranial Doppler Ultrasound
      • 5.2.2. Global Aneurysmal Subarachnoid Hemorrhage by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Aneurysmal Subarachnoid Hemorrhage by: Drug Class (Value)
        • 5.2.3.1. Calcium Channel Blocker
        • 5.2.3.2. Opioid Analgesic
        • 5.2.3.3. Osmotic Agent
        • 5.2.3.4. Anticonvulsant
        • 5.2.3.5. Stool Softener
        • 5.2.3.6. Others
      • 5.2.4. Global Aneurysmal Subarachnoid Hemorrhage Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Aneurysmal Subarachnoid Hemorrhage (Price)
      • 5.3.1. Global Aneurysmal Subarachnoid Hemorrhage by: Type (Price)
  • 6. Aneurysmal Subarachnoid Hemorrhage: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Edge Therapeutics, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Actelion Pharmaceuticals Ltd. (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Arbor Pharmaceuticals Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mayfield Brain & Spine (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GE Healthcare (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Koninklijke Philips N.V. (Netherland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Siemens AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Trivitron Healthcare (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Toshiba Medical Systems Corporation (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Aneurysmal Subarachnoid Hemorrhage Sale, by Type, Application, Drug Class and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Aneurysmal Subarachnoid Hemorrhage (Value)
      • 7.2.1. Global Aneurysmal Subarachnoid Hemorrhage by: Type (Value)
        • 7.2.1.1. Computed Tomography (CT) Scan
        • 7.2.1.2. Magnetic Resonance Imaging (MRI)
        • 7.2.1.3. Lumbar Puncture
        • 7.2.1.4. Xanthochromia
        • 7.2.1.5. Cerebral Angiography
        • 7.2.1.6. Transcranial Doppler Ultrasound
      • 7.2.2. Global Aneurysmal Subarachnoid Hemorrhage by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Aneurysmal Subarachnoid Hemorrhage by: Drug Class (Value)
        • 7.2.3.1. Calcium Channel Blocker
        • 7.2.3.2. Opioid Analgesic
        • 7.2.3.3. Osmotic Agent
        • 7.2.3.4. Anticonvulsant
        • 7.2.3.5. Stool Softener
        • 7.2.3.6. Others
      • 7.2.4. Global Aneurysmal Subarachnoid Hemorrhage Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Aneurysmal Subarachnoid Hemorrhage (Price)
      • 7.3.1. Global Aneurysmal Subarachnoid Hemorrhage by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Aneurysmal Subarachnoid Hemorrhage: by Type(USD Million)
  • Table 2. Aneurysmal Subarachnoid Hemorrhage Computed Tomography (CT) Scan , by Region USD Million (2018-2023)
  • Table 3. Aneurysmal Subarachnoid Hemorrhage Magnetic Resonance Imaging (MRI) , by Region USD Million (2018-2023)
  • Table 4. Aneurysmal Subarachnoid Hemorrhage Lumbar Puncture , by Region USD Million (2018-2023)
  • Table 5. Aneurysmal Subarachnoid Hemorrhage Xanthochromia , by Region USD Million (2018-2023)
  • Table 6. Aneurysmal Subarachnoid Hemorrhage Cerebral Angiography , by Region USD Million (2018-2023)
  • Table 7. Aneurysmal Subarachnoid Hemorrhage Transcranial Doppler Ultrasound , by Region USD Million (2018-2023)
  • Table 8. Aneurysmal Subarachnoid Hemorrhage: by Application(USD Million)
  • Table 9. Aneurysmal Subarachnoid Hemorrhage Hospitals , by Region USD Million (2018-2023)
  • Table 10. Aneurysmal Subarachnoid Hemorrhage Clinics , by Region USD Million (2018-2023)
  • Table 11. Aneurysmal Subarachnoid Hemorrhage Others , by Region USD Million (2018-2023)
  • Table 12. Aneurysmal Subarachnoid Hemorrhage: by Drug Class(USD Million)
  • Table 13. Aneurysmal Subarachnoid Hemorrhage Calcium Channel Blocker , by Region USD Million (2018-2023)
  • Table 14. Aneurysmal Subarachnoid Hemorrhage Opioid Analgesic , by Region USD Million (2018-2023)
  • Table 15. Aneurysmal Subarachnoid Hemorrhage Osmotic Agent , by Region USD Million (2018-2023)
  • Table 16. Aneurysmal Subarachnoid Hemorrhage Anticonvulsant , by Region USD Million (2018-2023)
  • Table 17. Aneurysmal Subarachnoid Hemorrhage Stool Softener , by Region USD Million (2018-2023)
  • Table 18. Aneurysmal Subarachnoid Hemorrhage Others , by Region USD Million (2018-2023)
  • Table 19. South America Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2018-2023)
  • Table 20. South America Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 21. South America Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 22. South America Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 23. Brazil Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 24. Brazil Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 25. Brazil Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 26. Argentina Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 27. Argentina Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 28. Argentina Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 29. Rest of South America Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 30. Rest of South America Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 31. Rest of South America Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 32. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2018-2023)
  • Table 33. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 34. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 35. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 36. China Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 37. China Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 38. China Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 39. Japan Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 40. Japan Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 41. Japan Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 42. India Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 43. India Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 44. India Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 45. South Korea Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 46. South Korea Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 47. South Korea Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 48. Taiwan Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 49. Taiwan Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 50. Taiwan Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 51. Australia Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 52. Australia Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 53. Australia Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 55. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 56. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 57. Europe Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2018-2023)
  • Table 58. Europe Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 59. Europe Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 60. Europe Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 61. Germany Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 62. Germany Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 63. Germany Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 64. France Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 65. France Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 66. France Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 67. Italy Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 68. Italy Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 69. Italy Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 70. United Kingdom Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 71. United Kingdom Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 72. United Kingdom Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 73. Netherlands Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 74. Netherlands Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 75. Netherlands Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 76. Rest of Europe Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 77. Rest of Europe Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 78. Rest of Europe Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 79. MEA Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2018-2023)
  • Table 80. MEA Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 81. MEA Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 82. MEA Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 83. Middle East Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 84. Middle East Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 85. Middle East Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 86. Africa Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 87. Africa Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 88. Africa Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 89. North America Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2018-2023)
  • Table 90. North America Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 91. North America Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 92. North America Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 93. United States Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 94. United States Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 95. United States Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 96. Canada Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 97. Canada Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 98. Canada Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 99. Mexico Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2018-2023)
  • Table 100. Mexico Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2018-2023)
  • Table 101. Mexico Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2018-2023)
  • Table 102. Aneurysmal Subarachnoid Hemorrhage: by Type(USD/Units)
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Aneurysmal Subarachnoid Hemorrhage: by Type(USD Million)
  • Table 113. Aneurysmal Subarachnoid Hemorrhage Computed Tomography (CT) Scan , by Region USD Million (2025-2030)
  • Table 114. Aneurysmal Subarachnoid Hemorrhage Magnetic Resonance Imaging (MRI) , by Region USD Million (2025-2030)
  • Table 115. Aneurysmal Subarachnoid Hemorrhage Lumbar Puncture , by Region USD Million (2025-2030)
  • Table 116. Aneurysmal Subarachnoid Hemorrhage Xanthochromia , by Region USD Million (2025-2030)
  • Table 117. Aneurysmal Subarachnoid Hemorrhage Cerebral Angiography , by Region USD Million (2025-2030)
  • Table 118. Aneurysmal Subarachnoid Hemorrhage Transcranial Doppler Ultrasound , by Region USD Million (2025-2030)
  • Table 119. Aneurysmal Subarachnoid Hemorrhage: by Application(USD Million)
  • Table 120. Aneurysmal Subarachnoid Hemorrhage Hospitals , by Region USD Million (2025-2030)
  • Table 121. Aneurysmal Subarachnoid Hemorrhage Clinics , by Region USD Million (2025-2030)
  • Table 122. Aneurysmal Subarachnoid Hemorrhage Others , by Region USD Million (2025-2030)
  • Table 123. Aneurysmal Subarachnoid Hemorrhage: by Drug Class(USD Million)
  • Table 124. Aneurysmal Subarachnoid Hemorrhage Calcium Channel Blocker , by Region USD Million (2025-2030)
  • Table 125. Aneurysmal Subarachnoid Hemorrhage Opioid Analgesic , by Region USD Million (2025-2030)
  • Table 126. Aneurysmal Subarachnoid Hemorrhage Osmotic Agent , by Region USD Million (2025-2030)
  • Table 127. Aneurysmal Subarachnoid Hemorrhage Anticonvulsant , by Region USD Million (2025-2030)
  • Table 128. Aneurysmal Subarachnoid Hemorrhage Stool Softener , by Region USD Million (2025-2030)
  • Table 129. Aneurysmal Subarachnoid Hemorrhage Others , by Region USD Million (2025-2030)
  • Table 130. South America Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2025-2030)
  • Table 131. South America Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 132. South America Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 133. South America Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 134. Brazil Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 135. Brazil Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 136. Brazil Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 137. Argentina Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 138. Argentina Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 139. Argentina Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 140. Rest of South America Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 141. Rest of South America Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 142. Rest of South America Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 143. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2025-2030)
  • Table 144. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 145. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 146. Asia Pacific Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 147. China Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 148. China Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 149. China Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 150. Japan Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 151. Japan Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 152. Japan Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 153. India Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 154. India Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 155. India Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 156. South Korea Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 157. South Korea Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 158. South Korea Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 159. Taiwan Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 160. Taiwan Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 161. Taiwan Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 162. Australia Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 163. Australia Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 164. Australia Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 165. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 166. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 167. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 168. Europe Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2025-2030)
  • Table 169. Europe Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 170. Europe Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 171. Europe Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 172. Germany Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 173. Germany Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 174. Germany Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 175. France Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 176. France Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 177. France Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 178. Italy Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 179. Italy Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 180. Italy Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 181. United Kingdom Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 182. United Kingdom Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 183. United Kingdom Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 184. Netherlands Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 185. Netherlands Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 186. Netherlands Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 187. Rest of Europe Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 188. Rest of Europe Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 189. Rest of Europe Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 190. MEA Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2025-2030)
  • Table 191. MEA Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 192. MEA Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 193. MEA Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 194. Middle East Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 195. Middle East Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 196. Middle East Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 197. Africa Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 198. Africa Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 199. Africa Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 200. North America Aneurysmal Subarachnoid Hemorrhage, by Country USD Million (2025-2030)
  • Table 201. North America Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 202. North America Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 203. North America Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 204. United States Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 205. United States Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 206. United States Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 207. Canada Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 208. Canada Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 209. Canada Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 210. Mexico Aneurysmal Subarachnoid Hemorrhage, by Type USD Million (2025-2030)
  • Table 211. Mexico Aneurysmal Subarachnoid Hemorrhage, by Application USD Million (2025-2030)
  • Table 212. Mexico Aneurysmal Subarachnoid Hemorrhage, by Drug Class USD Million (2025-2030)
  • Table 213. Aneurysmal Subarachnoid Hemorrhage: by Type(USD/Units)
  • Table 214. Research Programs/Design for This Report
  • Table 215. Key Data Information from Secondary Sources
  • Table 216. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Aneurysmal Subarachnoid Hemorrhage: by Type USD Million (2018-2023)
  • Figure 5. Global Aneurysmal Subarachnoid Hemorrhage: by Application USD Million (2018-2023)
  • Figure 6. Global Aneurysmal Subarachnoid Hemorrhage: by Drug Class USD Million (2018-2023)
  • Figure 7. South America Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 8. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 9. Europe Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 10. MEA Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 11. North America Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 12. Global Aneurysmal Subarachnoid Hemorrhage: by Type USD/Units (2018-2023)
  • Figure 13. Global Aneurysmal Subarachnoid Hemorrhage share by Players 2023 (%)
  • Figure 14. Global Aneurysmal Subarachnoid Hemorrhage share by Players (Top 3) 2023(%)
  • Figure 15. Global Aneurysmal Subarachnoid Hemorrhage share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Edge Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Edge Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 19. Actelion Pharmaceuticals Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 20. Actelion Pharmaceuticals Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 21. Arbor Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Arbor Pharmaceuticals Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Mayfield Brain & Spine (United States) Revenue, Net Income and Gross profit
  • Figure 24. Mayfield Brain & Spine (United States) Revenue: by Geography 2023
  • Figure 25. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 26. GE Healthcare (United States) Revenue: by Geography 2023
  • Figure 27. Koninklijke Philips N.V. (Netherland) Revenue, Net Income and Gross profit
  • Figure 28. Koninklijke Philips N.V. (Netherland) Revenue: by Geography 2023
  • Figure 29. Siemens AG (Germany) Revenue, Net Income and Gross profit
  • Figure 30. Siemens AG (Germany) Revenue: by Geography 2023
  • Figure 31. Trivitron Healthcare (India) Revenue, Net Income and Gross profit
  • Figure 32. Trivitron Healthcare (India) Revenue: by Geography 2023
  • Figure 33. Toshiba Medical Systems Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 34. Toshiba Medical Systems Corporation (Japan) Revenue: by Geography 2023
  • Figure 35. Global Aneurysmal Subarachnoid Hemorrhage: by Type USD Million (2025-2030)
  • Figure 36. Global Aneurysmal Subarachnoid Hemorrhage: by Application USD Million (2025-2030)
  • Figure 37. Global Aneurysmal Subarachnoid Hemorrhage: by Drug Class USD Million (2025-2030)
  • Figure 38. South America Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 39. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 40. Europe Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 41. MEA Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 42. North America Aneurysmal Subarachnoid Hemorrhage Share (%), by Country
  • Figure 43. Global Aneurysmal Subarachnoid Hemorrhage: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Edge Therapeutics, Inc. (United States)
  • Actelion Pharmaceuticals Ltd. (Switzerland)
  • Arbor Pharmaceuticals Inc. (United States)
  • Mayfield Brain & Spine (United States)
  • GE Healthcare (United States)
  • Koninklijke Philips N.V. (Netherland)
  • Siemens AG (Germany)
  • Trivitron Healthcare (India)
  • Toshiba Medical Systems Corporation (Japan)
Select User Access Type

Key Highlights of Report


Jan 2024 232 Pages 91 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Aneurysmal Subarachnoid Hemorrhage Quantitative research analysis
Global Aneurysmal Subarachnoid Hemorrhage Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Edge Therapeutics, Inc. (United States), Actelion Pharmaceuticals Ltd. (Switzerland), Arbor Pharmaceuticals Inc. (United States), Mayfield Brain & Spine (United States), GE Healthcare (United States), Koninklijke Philips N.V. (Netherland), Siemens AG (Germany), Trivitron Healthcare (India) and Toshiba Medical Systems Corporation (Japan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancements in the Treatment and Devices Used for Postpartum hemorrhage " is seen as one of major influencing trends for Aneurysmal Subarachnoid Hemorrhage Market during projected period 2023-2030.
The Aneurysmal Subarachnoid Hemorrhage market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Aneurysmal Subarachnoid Hemorrhage Report?

Have a Query? Click Here

Other Related Reports

Phenylketonuria Treatment Comprehensive Study by Type (Drugs (Kuvan, Pegvaliase and Others), Dietary Supplement), Application (Hospital Pharmacies, Drug Stores, Online Pharmacies, Pediatric Clinics),...
$ 3650
Nerve Repair and Regeneration Comprehensive Study by Type (Neurostimulation Devices, Neuromodulation Devices (Sacral Nerve Stimulation Devices (SNS), Vagus Nerve Stimulation Devices (VNS), Spinal Cor...
$ 3750
mRNA Vaccines & Therapeutics Comprehensive Study by Type (Standardization of Cancer Treatment MRNA Vaccine, Individualized Cancer Treatment MRNA Vaccine, Infectious Disease Treatment MRNA Vaccine, In...
$ 3750
Antibody Services Comprehensive Study by Type (Polyclonal antibody, Monoclonal antibody, Murine, Chimeric, Humanize, Other), Application (Gastroenterology, Rheumatology, Infection, Cardiology, Hemato...
$ 3650
Liver Disease Treatment Comprehensive Study by Application (Hospital, Clinic, Others), Disease Type (Hepatitis, Autoimmune diseases, Liver tumor, Chronic liver disease, Fatty liver disease.), Treatme...
$ 3650
Cancer Pain Therapeutics Comprehensive Study by Type (Opioids, Non-Steroidal Anti-Inflammatory Drugs, Others), Application (Related Immunotherapy, Radiotherapy, Chemotherapy, Hormone Therapy), End Us...
$ 3350